Aurinia Pharmaceuticals Inc AUPH
$16.57
+0.76%
at last close
Market Cap$2.19 billion
P/E Ratio—
Div Yield—
Volume240.4K
52-Week Range
$10.34$19.25
Analyst Ratings
- Consensus
- Hold — 1 Buy · 2 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $17.67 (+6.7% upside)
Key Stats
- Today's Range
- $16.24 – $16.62
- 50-Day Range
- $14.36 – $17.80
- 52-Week Range
- $10.34 – $19.25
- Volume
- 240K shs
- Average Volume
- 896K shs
- Market Cap
- $2.19 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 7.43%
- Days to Cover
- 8.65
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Related Stocks
Compare head-to-head: AUPH vs LLY·AUPH vs JNJ·AUPH vs ABBV·AUPH vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.